-
1
-
-
77954956519
-
Montanide ISA 51 VG as Adjuvant for Human Vaccines
-
Bonhoure F, Gaucheron J. Montanide ISA 51 VG as Adjuvant for Human Vaccines. J Immunother. 2006;29:647-648.
-
(2006)
J. Immunother.
, vol.29
, pp. 647-648
-
-
Bonhoure, F.1
Gaucheron, J.2
-
2
-
-
0034793424
-
Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes
-
Slingluff CL Jr, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012-3024.
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 3012-3024
-
-
Slingluff Jr., C.L.1
Yamshchikov, G.2
Neese, P.3
-
3
-
-
20044373641
-
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
-
Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J IImmunol. 2005;174:3080-3086.
-
(2005)
J. IImmunol
, vol.174
, pp. 3080-3086
-
-
Chianese-Bullock, K.A.1
Pressley, J.2
Garbee, C.3
-
4
-
-
58149288270
-
Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines
-
Slingluff CL Jr, Yamshchikov GV, Hogan KT, et al. Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann Surg Oncol. 2008;15:3538-3549.
-
(2008)
Ann. Surg. Oncol.
, vol.15
, pp. 3538-3549
-
-
Slingluff Jr., C.L.1
Yamshchikov, G.V.2
Hogan, K.T.3
-
5
-
-
54449097809
-
Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens
-
Slingluff CL Jr, Petroni GR, Olson W, et al. Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008;26:4973-4980.
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 4973-4980
-
-
Slingluff Jr., C.L.1
Petroni, G.R.2
Olson, W.3
-
6
-
-
72549116845
-
+ T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial
-
+ T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial. Clin Cancer Res. 2009;15:7036-7044.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 7036-7044
-
-
Slingluff Jr., C.L.1
Petroni, G.R.2
Olson, W.C.3
-
7
-
-
42649117473
-
A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
-
Chianese-Bullock KA, Irvin WP Jr, Petroni GR, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother. 2008;31:420-430.
-
(2008)
J. Immunother.
, vol.31
, pp. 420-430
-
-
Chianese-Bullock, K.A.1
Irvin Jr., W.P.2
Petroni, G.R.3
-
8
-
-
35948972459
-
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting
-
Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 2007;13:6386-6395.
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 6386-6395
-
-
Slingluff Jr., C.L.1
Petroni, G.R.2
Chianese-Bullock, K.A.3
-
9
-
-
14044259609
-
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
-
Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474-4485.
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 4474-4485
-
-
Slingluff Jr., C.L.1
Petroni, G.R.2
Yamshchikov, G.V.3
-
10
-
-
0642311904
-
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells
-
Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016-4026.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 4016-4026
-
-
Slingluff Jr., C.L.1
Petroni, G.R.2
Yamshchikov, G.V.3
-
11
-
-
77954956955
-
+ T cell responses: Outcome of a multicenter randomized trial [abstract]
-
Abstract #3008, ASCO annual meeting, Orlando, FL
-
+ T cell responses: outcome of a multicenter randomized trial [abstract]. J Clin Oncol (Meeting Abstracts) 2009;27: Abstract #3008, ASCO annual meeting, Orlando, FL.
-
(2009)
J. Clin. Oncol. (Meeting Abstracts)
, vol.27
-
-
Slingluff Jr., C.L.1
Petroni, G.R.2
Olson, W.C.3
-
12
-
-
77954958474
-
Effects of melanoma-derived helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine [abstract]
-
Slingluff C, Petroni G, Chianese-Bullock K, et al. Effects of melanoma-derived helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine [abstract]. J Immunother. 2009;32:976.
-
(2009)
J. Immunother.
, vol.32
, pp. 976
-
-
Slingluff, C.1
Petroni, G.2
Chianese-Bullock, K.3
-
13
-
-
13744260910
-
Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members
-
Hogan KT, Sutton JN, Chu KU, et al. Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunol Immunother. 2005;54:359-371.
-
(2005)
Cancer Immunol. Immunother.
, vol.54
, pp. 359-371
-
-
Hogan, K.T.1
Sutton, J.N.2
Chu, K.U.3
-
14
-
-
0033102344
-
Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development [published erratum appears in
-
Kittlesen DJ, Thompson LW, Gulden PH, et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development [published erratum appears in J Immunol 1999;162:3106].
-
(1999)
J. Immunol.
, vol.162
, pp. 3106
-
-
Kittlesen, D.J.1
Thompson, L.W.2
Gulden, P.H.3
-
15
-
-
0032030641
-
-
J Immunother. 1998;160:2099-2106.
-
(1998)
J. Immunother.
, vol.160
, pp. 2099-2106
-
-
-
17
-
-
70350135349
-
A phase III multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract]
-
abstract CRA9011
-
Schwartzentruber DJ, Lawson D, Richards J, et al. A phase III multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma [abstract]. J Clin Oncol (Meeting Abstracts). 2009;27: abstract CRA9011.
-
(2009)
J. Clin. Oncol. (Meeting Abstracts)
, vol.27
-
-
Schwartzentruber, D.J.1
Lawson, D.2
Richards, J.3
-
18
-
-
33646779561
-
Altered CD8 (+) T-cell responses when immunizing with multiepitope peptide vaccines
-
Rosenberg SA, Sherry RM, Morton KE, et al. Altered CD8 (+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother. 2006;29:224-231.
-
(2006)
J. Immunother.
, vol.29
, pp. 224-231
-
-
Rosenberg, S.A.1
Sherry, R.M.2
Morton, K.E.3
-
19
-
-
60849091328
-
Multipeptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies
-
Chianese-Bullock KA, Lewis ST, Sherman NE, et al. Multipeptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. Vaccine. 2009;27:1764-1770.
-
(2009)
Vaccine
, vol.27
, pp. 1764-1770
-
-
Chianese-Bullock, K.A.1
Lewis, S.T.2
Sherman, N.E.3
-
20
-
-
77954951870
-
The melanoma vaccine microenvironment: Do negative contributors of immune function compartmentalize the vaccine site? [abstract]
-
Schaefer J, Deacon D, Smolkin M, et al. The melanoma vaccine microenvironment: do negative contributors of immune function compartmentalize the vaccine site? [abstract]. J Immunother. 2009;32:975-976.
-
(2009)
J. Immunother.
, vol.32
, pp. 975-976
-
-
Schaefer, J.1
Deacon, D.2
Smolkin, M.3
-
21
-
-
77954951500
-
Peptide/incomplete Freund adjuvant emulsion depots are a graveyard for tumor antigen-specific CD8+ T cells [abstract]
-
Overwijk W, Hailemichael Y, Dai Z, et al. Peptide/incomplete Freund adjuvant emulsion depots are a graveyard for tumor antigen-specific CD8+ T cells [abstract]. J Immunother. 2009;32:971.
-
(2009)
J. Immunother.
, vol.32
, pp. 971
-
-
Overwijk, W.1
Hailemichael, Y.2
Dai, Z.3
|